Strategies for treating HIV-related lipodystrophy

Bibliography

• JOFFE BI, PANZ VR, RAAL FJ: From lipodystrophy syndromes to diabetes mellitus. Lancet (2001) 357:1379–1380.
   PubMed Web of Science ®Google Scholar
• GARG A: Lipodystrophies. Am. j Med. (2000) 108:143–152.
   Google Scholar
• •General review on lipodystrophies.
   Google Scholar
• MARTINEZ E, GATELL JM: Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. Curr. Opin Infect. Dis. (1999) 12:13–19.
   PubMed Web of Science ®Google Scholar
• PAGANELLI R, MEZZAROMA I, MAZZONE AM, PINTER E, AIUTI F: Leptin levels in HIV-positive patients treated with HAART. AIDS (1999) 13:2479.
   PubMed Web of Science ®Google Scholar
• MULLIGAN K, GRUNFELD C, TAI VW et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. AIDS (2000) 23:35–43.
   Google Scholar
• •Metabolic abnormalities induced by protease inhibitors are not necessarily accompanied by body fat changes.
   Google Scholar
• GERVASONI C, RID OLFO AL, TRIFIROG et al.: Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS (1999) 13:465–471.
   PubMed Web of Science ®Google Scholar
• HOY J, HUDSON J, LAW M, COOPERDA FOR THE PIILR INVESTIGATORS: Osteopenia in a randomized, multicenter study of protease inhibitor substitution in patients with the lipodystrophy syndrome and well-controlled HIV viremia. 7th Conference on Retrovinnes and Opportunistic Infections. San Francisco, USA (2000) (Abstract) 208.
   Google Scholar
• NOLAN D, UPTON R, MCKINNON Eet al: Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS (2001) 15:1275–1280.
   PubMed Web of Science ®Google Scholar
• HUANG JS, RIETSCHEL P, HADIGAN C, ROSENTHAL DI, GRINSPOON S: Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS (2001) 15:975–982.
   PubMed Web of Science ®Google Scholar
• BRINKMAN K, SMEITINK JA, ROMIJN JA et al.: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet (1999) 354:1112–1115.
   PubMed Web of Science ®Google Scholar
• •Mitochondrial toxicity hypothesis for lipodystrophy in HIV-infected patients.
   Google Scholar
• JOHN M, MOORE CB, JAMES IR et al:
   Google Scholar
• •• Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS (2001) 15:717–723.
   Google Scholar
• VIRABEN R, AQUILINA C: Indinavir- associated lipodystrophy. AIDS (1998) 12:F37–F39.
   PubMed Web of Science ®Google Scholar
• CARR A, SAMARAS K, BURTON S et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12:F51–F58.
   PubMed Web of Science ®Google Scholar
• ••First comprehensive description oflipodystrophy in HIV-infected patients.
   Google Scholar
• PURNELL JQ, ZAMBON A, KNOPP RH et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS (2000) 14:51–57.
   PubMed Web of Science ®Google Scholar
• •Metabolic abnormalities induced by the protease inhibitor ritonavir also occur in non-HIV-infected individuals.
   Google Scholar
• PURO V, FOR THE ITALIAN REGISTRY OF ANTIRETRO VIRAL POST-EXPOSURE PROPHYLAXIS: Effect of short-course of antiretroviral agents on serum triglycerides of healthy individuals. AIDS (2000) 14:2407–2408.
   PubMed Web of Science ®Google Scholar
• MARTINEZ E, CASAMITJANA R, CONGET I, GATELL JM: Protease inhibitor-associated hyperinsulinaemia. AIDS (1999) 12:2077–2079.
   Web of Science ®Google Scholar
• NOOR M, LO J, MULLIGAN K et al.: Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS (2001) 15:11–
   PubMed Web of Science ®Google Scholar
• CARR A, SAMARAS K, CHISHOLM DJ, COOPER DA: Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet (1998) 351: 1881-1883.
   Google Scholar
• MARTINEZ E, GATELL JM: Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet (1998) 352:821–822.
   PubMed Web of Science ®Google Scholar
• FLEXNER C: HIV-protease inhibitors. N Engl. J. Med. (1998) 338:1281–1292.
   PubMed Web of Science ®Google Scholar
• ••General review on HIV proteaseinhibitors.
   Google Scholar
• MAGDE S, KINLOCH-DE-LOES S, MERCEY D, JOHNSON MA, WELLER IVD: Lipodystrophy in patients naive to HIV protease inhibitors. AIDS (1999) 13:735–737.
   PubMed Web of Science ®Google Scholar
• ALDEEN T, WELLS C, HAY E DAVIDSON E LAU R: Lipodystrophy associated with nevirapine-containing antiretroviral therapies. AIDS (1999) 13:865–867.
   PubMed Web of Science ®Google Scholar
• MALLAL SA, JOHN M, MOORE CB et al.: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS (2000) 14:1309–1316.
   PubMed Web of Science ®Google Scholar
• •Additive effect of nucleoside analogue reverse transcriptase inhibitors and protease inhibitors in the development of lipodystrophy in HIV-infected patients.
   Google Scholar
• VAN DER VALK M, GISOLF EH, REISS P et al.: Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS (2001) 15:847–855.
   Google Scholar
• JOHN M, NOLAN D, MALLAL S: Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Ther (2001) 6:9–20.
   PubMed Web of Science ®Google Scholar
• MURATA H, HRUZ PW, MUECKLER M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. j Biol. Chem. (2000) 275:20251–20254.
   PubMed Web of Science ®Google Scholar
• CARON M, AUCLAIR M, VIGOUROUX C et al: The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes (2001) 50:1378–1388.
   PubMed Web of Science ®Google Scholar
• NOLTE LA, YARASHESKI KE, KAWANAKA K et al.: The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes (2001) 50:1397–1401.
   PubMed Web of Science ®Google Scholar
• RUDICH A, VANOUNOU S, RIESENBERG K et al: The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes (2001) 50:1425–1431.
   PubMed Web of Science ®Google Scholar
• GAOU I, MALLITI M, GUIMONT MC et al.: Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. j Pharmacol. Exp. Ther. (2001) 297:516–523.
   PubMed Web of Science ®Google Scholar
• MOYLE G: Mitochondrial toxicity hypothesis for lipoatrophy: a refutation. AIDS (2001) 15:413–415.
   PubMed Web of Science ®Google Scholar
• •Elegant exhibition of the limitations to the mitochondrial toxicity hypothesis for lipodystrophy in HIV-infected patients.
   Google Scholar
• KOTLER DP, ROSENBAUM K, WANG J, PIERSON RN: Studies of body composition and fat distribution in HIV-infected and control subjects. I AIDS (1999) 20:228–237.
   Web of Science ®Google Scholar
• •Evidence for changes consistent with lipodystrophy in HIV-infected patients prior to HAART.
   Google Scholar
• WARD DJ, DELANCY KM, MOORMAN AC et al.:Description of lipodystrophy in the HIV Outpatient Study (HOPS). First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV San Diego, USA (1999) (Abstract 14).
   Google Scholar
• WURTZ R, CEASER S: Adipose redistribution in human immunodeficiency virus-seropositive patients: association with CD4 response. Clin. Infect. Dis. (2000) 31:1497–1498.
   PubMed Web of Science ®Google Scholar
• NORBIATO G, TRIFIRO G, GALLI M, GERVASONI C, CLERICI M: Fat redistribution in HIV-infected patients: a new hormonal-immune disorder? Ann. NY Acad. Sci. (2000) 917:951–955.
   PubMed Web of Science ®Google Scholar
• MARTINEZ E, MOCROFT A, GARCIA-VIEJO MA et al.: Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet (2001) 357:592–598.
   PubMed Web of Science ®Google Scholar
• ••First prospective study showing data onincidence and risk factors on lipodystrophy in HIV-infected patients. Duration of total exposure to antiretroviral therapy (instead of to a single drug) and additional host-related factors (instead of drug factors alone) emerge as key points for the risk of lipodystrophy in HIV-infected patients.
   Google Scholar
• CAPILUPPI B, CIUFFREDA D, SCIANDRA M, MARRONI M, TAMBUSSI G, LAZZARIN A: Metabolic disorders in a cohort of patients treated with highly aggressive antiretroviral therapies during primary HIV-1 infection. AIDS (2000) 14: 1861-1862.
   Google Scholar
• MIRO JM, MARTINEZ E, GARCIA F et al.: Incidence of lipodystrophy in patients with primary HIV-1 infection treated with HAART. 7th Conference on Retro viruses and Opportunistic Infections. San Francisco, USA (2000) (Abstract 12).
   Google Scholar
• MILLER J, CARR A, SMITH D et al.: Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS (2000) 14:2406–2407.
   PubMed Web of Science ®Google Scholar
• GOUJARD C, BOUFASSA F, DEVEAU C, LASKRI D, MEYER L, FOR THE PRIMO GROUP: Incidence of clinical lipodystrophy in HIV-1-infected patients treated during primary infection. AIDS (2001) 15:282–284.
   PubMed Web of Science ®Google Scholar
• BATTERHAM MJ, GARSIA R, GREENOP PA: Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy: Diet FRS Study. AIDS (2000) 14:1839–1843.
   PubMed Web of Science ®Google Scholar
• SAMARAS K, KELLY PJ, CHIANO MN, SPECTOR TD, CAMPBELL LV: Genetic and environmental influences on total-body and central abdominal fat: the effect of physical activity in female twins. Ann. Intern. Med. (1999) 130:873–882.
   PubMed Web of Science ®Google Scholar
• ZYLBERBERG H, NALPAS B, POL S, BRECHOT C, VIARD JP: Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy. AIDS (2000) 14:2055.
   PubMed Web of Science ®Google Scholar
• CORCORAN C, GRINSPOON S: Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl. J. Med (1999) 340:1740–1750.
   PubMed Web of Science ®Google Scholar
• •General review on treatment of wasting in HIV-infected patients.
   Google Scholar
• 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR (1992) 41:1–19.
   Google Scholar
• PALELLA FJ, DELANEY KM, MOORMAN AC et al.:Declining morbidity and mortality among patients with advanced HIV infection. N Engl. J Med. (1998) 338:853–860.
   PubMed Web of Science ®Google Scholar
• MO CROFT A, VELLA S, BENFIELD TL et al. FOR THE EUROSIDA STUDY GROUP: Changing patterns of mortality across Europe in patients infected with HIV. Lancet (1998) 352:1725–1730.
   PubMed Web of Science ®Google Scholar
• WONG JK, HAZAREH M, GUNTHARD HF et al.:Recovery of replication-competent HIV despite prolonged suppression of HIV viremia. Science (1997) 278:1211–1215.
   Google Scholar
• FINZI D, HERMANKOVA M, PIERSON T et al.: Identification of a reservoir of human immunodeficiency virus-1 in patients on highly active antiretroviral therapy. Science (1997) 278:1295–1300.
   PubMed Web of Science ®Google Scholar
• SILVA M, SKOLNIK E GORBACH S et al.: The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS (1998) 12:1645–1651.
   Google Scholar
• CARBONNEL F, MASLO C, BEAUGERIE L et al.:Effect of indinavir on HIV-related wasting. AIDS (1998) 12:1777–1784.
   PubMed Web of Science ®Google Scholar
• PERNERSTORFER-SCHOEN H, SCHINDLER K, PARSCHALK B et al.: Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS (1999) 13:2389–2396.
   PubMed Web of Science ®Google Scholar
• YANOVSKI JA, MILLER KD, KINO T et al.: Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. Eridocnhol. Metab. (1999) 84:1925–1931.
   PubMed Web of Science ®Google Scholar
• SCHWENK A, KREMER G, CORNELY 0 et al.: Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients. Nutrition (1999) 15:453–457.
   Google Scholar
• WANKE CA, SILVA M, KNOX TA, FORRESTER J, SPEIGELMAN D, GORBACH SL: Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Chu. Infect. Dis. (2000) 31:803–805.
   PubMed Web of Science ®Google Scholar
• SHEVITZ AB, KNOX TA, SPEIGELMAN D, ROUBENOFF R, GORBACH SL, SKOLNIK P: Elevated resting energy expenditure among seropositive persons receiving highly active antiretroviral therapy. AIDS (1999) 13:1351–1357.
   PubMed Web of Science ®Google Scholar
• GRUNFELD C, KOTLER DP, HAMADEH R, TIERNEY A, WANG J, PIERSON RN JR: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. (1989) 86:27–31.
   PubMed Web of Science ®Google Scholar
• LEDRU E, CHRISTEFF N, PATEY 0, DE TRUCHIS P, MELCHIOR JC, GOUGEON ML: Alteration of tumor necrosis factor-a T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood (2000) 95:3191–3198.
   PubMed Web of Science ®Google Scholar
• •First evidence implicating cytokine disturbance on the aetiopathogenesis of lipodystrophy in HIV-infected patients.
   Google Scholar
• MYNARCIK DC, MCNURLAN MA, STEIGBIGEL RT, FUHRER J, GELATO MC: Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. j AIDS (2000) 25:312–321.
   PubMed Web of Science ®Google Scholar
• SELLMEYER DE, GRUNFELD C: Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocrine Rev.(1996) 17:518–532.
   PubMed Web of Science ®Google Scholar
• ••General review on endocrine abnormalities in HIV-infected patients prior to the advent of lipodystrophy.
   Google Scholar
• SCEVOLA D, DI MATTEO A, UBERTI F, MINOIA G, POLETTI F, FAGA A: Reversal of cachexia in patients treated with potent antiretroviral therapy. The AIDS Reader (2000) 10:365–375.
   PubMedGoogle Scholar
• HADIGAN C, MEIGS JB, CORCORAN C eta].: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. an. Infect. Dis. (2001) 32:130–139.
   Google Scholar
• ••Metabolic disturbances in HIV-infectedpatients show an increased cardiovascular risk profile.
   Google Scholar
• GINSBERG HN: Insulin resistance and cardiovascular disease. j an. Invest. (2000) 106:459–465.
   PubMedGoogle Scholar
• DUBE MP: Disorders of glucose metabolism in patients infected with human immunodeficiency virus. arr. Infect. Dis. (2000) 31:1467–1475.
   PubMed Web of Science ®Google Scholar
• MARTINEZ E, GARCIA MA, CONGET I et al.:Incidence, characteristics, and prognosis of diabetes mellitus associated with protease inhibitors. 8th Conference on Retro viruses and Opportunistic Infections. Chicago, Usa (2001) (Abstract 16).
   Google Scholar
• KISSEBAH AH, KRAKOWER GR: Regional adiposity and morbidity. Physic] Rev (1994) 74:761–811.
   PubMed Web of Science ®Google Scholar
• ••General review on the morbidity associatedwith increased intra-abdominal fat.
   Google Scholar
• NATIONAL CHOLESTEROL EDUCATION PROGRAM: Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation (1994) 89:1329–1445.
   Web of Science ®Google Scholar
• •Recommendations for the management of hypercholesterolaemia in the general population.
   Google Scholar
• HOKANSON JE, AUSTIN MA: Plasma triglyceride level is a risk factor independent of HDL cholesterol level: a meta-analysis of population-based prospective studies. Cardiovasc. Risk (1996) 3:213–219.
   PubMedGoogle Scholar
• MAGGI P, SERIO G, EPIFANI G etal.: Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS (2000) 14:F123–F128.
   Google Scholar
• •Increased risk for atherosclerosis in HIV-infected patients associated with protease inhibitor therapy.
   Google Scholar
• DEPAIRON M, CHESSEX S, SUDRE P et al.: Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS (2001) 15:329–334.
   PubMed Web of Science ®Google Scholar
• •Increased risk for atherosclerosis in HIV-infected patients not associated with protease inhibitor therapy but with other non-drug related factors that are similar to those ones in the general population.
   Google Scholar
• HENRY K, MELROE H, HUEBSCH J et al.: Severe premature coronary artery disease with protease inhibitors. Lancet (1998) 351:1328.
   PubMed Web of Science ®Google Scholar
• BEHRENS G, SCHMIDT H, MEYER D, STOLL M, SCHMIDT RE: Vascular complications associated with the use of HIV protease inhibitors. Lancet (1998) 351:1958.
   PubMed Web of Science ®Google Scholar
• VITTECOQ D, ESCAUT L, MONSUEZ JJ: Vascular complications associated with the use of HIV protease inhibitors. Lancet (1998) 351:1959.
   PubMed Web of Science ®Google Scholar
• JOTTE A, SCHWENK A, FRANZEN C et al.: Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? AIDS (1999) 13: 1796-1797.
   Google Scholar
• KOPPEL K, BRATT G, RAJS J: Suddencardiac death in a patient on 2 years of highly active antiretroviral therapy: a case report. AIDS (1999) 13: 1993-1994.
   Google Scholar
• MARY-KRAUSE M, COTTE L, SIMON-COUTELLIER A et al.: Myocardial infarction in HIV seropositive men in the era of HAART treatments in France. XIII International AIDS Conference. Durban, South Africa (2000) (Abstract WePeB4231).
   Google Scholar
• •Evidence for an excess risk of myocardial infarction in HIV-infected patients on HAART.
   Google Scholar
• VALDEZ H, CHOWDHRY TK, ASAAD R et al.: Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Chu. Infect. Dis. (2001) 32:1487–1493.
   PubMed Web of Science ®Google Scholar
• •Causes of mortality of HIV-infected patients in the era of HAART.
   Google Scholar
• CARR A, SAMARAS K, THORISDOTTIR A, KAUFMANN GR, CHISHOLM DJ, COOPER DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet (1999) 353:2093–2099.
   PubMed Web of Science ®Google Scholar
• ••First study on the characteristics andevolution of lipodystrophy in HIV-infected patients.
   Google Scholar
• HEATH KV, HOGG RS, CHAN KJ et al.: Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS (2001) 15:231–239.
   PubMed Web of Science ®Google Scholar
• MARTINEZ E, GARCIA-VIEJO MA, BLANCH J, GATELL JM: Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Safety (2001) 24:157–166.
   PubMed Web of Science ®Google Scholar
• ••General review on the impact of lipodystrophy on the quality of life of HIV-infected patients.
   Google Scholar
• COLLINS E, WAGNER C, WALMSLEY S: Psychological impact of the lipodystrophy syndrome in HIV infection. The AIDS Reader (2000) 10:546–551.
   PubMedGoogle Scholar
• DUKERS NHTM, STOLTE IG, ALBRECHT N, COUTINHO RA, DE WIT JBF: The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men. AIDS (2001) 15:812–813.
   PubMed Web of Science ®Google Scholar
• CLEEMAN JI: Detection and evaluation ofdyslipoproteinemia. Endocrinology and Metabolism Clinics of North America (1998) 27:597–611.
   PubMed Web of Science ®Google Scholar
• THE EXPERT COMMITTEE ON THE DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS: Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care (1998) 21 (Suppl. 1):55–519.
   Google Scholar
• SAINT-MARC T, PARTISANI M, POIZOT-MARTIN I et al.:Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS (2000) 14:37–49.
   PubMed Web of Science ®Google Scholar
• •Differentiation of at least two syndromes (lipoatrophy and lipoaccumulation) in HIV-infected patients with lipodystrophy.
   Google Scholar
• SHUTER J, CHANG CJ, KLEIN RS: Prevalence and predictive value of overweight in an urban HIV care clinic. J. AIDS (2001) 26:291–297.
   PubMed Web of Science ®Google Scholar
• KINGSLEY L, SMITE, RIDDLER S et al.: Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS). 8th Conference on Retro viruses and Opportunistic Infections. Chicago, USA (2001) (Abstract 538).
   Google Scholar
• ••Suggestion for an stabilisation in theprevalence and evolution of lipodystrophy in HIV-infected patients along time.
   Google Scholar
• CARPENTER C, MAHAJAN A, DISPIGNO M etal.: Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy: a 3.5 year study. The 1st L45 Conference on HIV pathogenesis and therapy Buenos Aires, Argentina (2001) (Abstract 502).
   Google Scholar
• DOMINGO P, MATIAS-GUIU X, PUJOL RM et al.: Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS (1999) 13:2261–2267.
   PubMed Web of Science ®Google Scholar
• •Evidence for fat apoptosis in HIV-infected patients with lipoatrophy.
   Google Scholar
• EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA (2001) 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• AMERICAN DIABETES ASSOCIATION: Standards of medical care for patients with diabetes mellitus. Diabetes Care (2001) 24 (Suppl. 1):533–544.
   Google Scholar
• KRIS-ETHERTON PM, TAYLOR DS, ZHAO G: Is there an optimal diet for the hypertriglyceridemic patient? J. Cardiovasc. Risk. (2000) 7:333–337.
   PubMedGoogle Scholar
• DUBE MP, SPRECHER D, HENRY K et al.: Prelimminary guidelines for the evaluation and management of dyslipemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Chit. Infect. Dis. (2000) 31:1216–1224.
   PubMed Web of Science ®Google Scholar
• ••First consensus guidelines for themanagement of metabolic abnormalities in HIV-infected patients with lipodystrophy.
   Google Scholar
• HELLERSTEIN MK, WU K, MCGRATH M et al.: Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immunodeficiency syndrome: relation to indices of cytokine production. J. AIDS (1996) 11:258–270.
   Web of Science ®Google Scholar
• GLAUBER H, WALLACE P, GRIVER K et al.: Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann. Intern. Med. (1988) 108:663–668.
   PubMed Web of Science ®Google Scholar
• RIVELLESE AA, MAFFETTONE A, IOVINE C et al.: Long-term effects of fish oil on insulin resistance and plasma lipoprotein in NIDDM patients with hypertriglyceridemia. Diabetes Care (1996) 19:1207–1213.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ ML: Soluble fiber and nondigestible carbohydrate effects on plasma lipids and cardiovascular risk. Curr. Opin. Lipidol (2001) 12:35–40.
   PubMed Web of Science ®Google Scholar
• AMERICAN DIABETES ASSOCIATION: Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care (2001) 24 (Suppl. 1):544–548.
   Google Scholar
• AMERICAN DIABETES ASSOCIATION: Diabetes mellitus and exercise. Diabetes Care (2001) 24 (Suppl. 1):S51–S56.
   Google Scholar
• PIGN ONE MP, PHILLIPS CJ, ATKINS D et al.: Screening and treating adults for lipid disorders (2). Am. Prey. Med (2001) 20(3 Suppl):77–89.
   PubMed Web of Science ®Google Scholar
• RUIZ L, NEGREDO E, DOMINGO P et al.: Clinical, virological, and immunological benefit of switching the protease inhibitor by nevirapine in HAART experienced patients suffering lipodystrophy: 36-week follow-up. 7th C011felE17Ce on Retro viruses and Opportunistic Infections. San Francisco, USA (2000) (Abstract 206).
   Google Scholar
• BARREIRO P, SORIANO V, BLANCO F et al.: Risks and benefits of replacing protease inhibitors by nevirapine in patients under long-term successful triple combination therapy. AIDS (2000) 14:807–812.
   PubMed Web of Science ®Google Scholar
• TEBAS P, YARASHESKI K, POWDERLY WG et al.: A prospective open-label pilot trial of a maintenance nevirapine-containing regimen in patients with undetectable viral loads on protease inhibitor regimens for at least 6 months. 7th Conference on Retro viruses and Opportunistic Infections. San Francisco, USA (2000) (Abstract 45).
   Google Scholar
• MARTINEZ E, CONGET I, LOZANO L, CASAMITJANA R, GATELL JM: Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS (1999) 13:805–810.
   PubMed Web of Science ®Google Scholar
• •First published study on the effect of switching antiretroviral therapy for treating lipodystrophy in HIV-infected patients.
   Google Scholar
• OPRAVIL M, YERLY S, LAZZARIN A et al.: Protease inhibitor class-sparing maintenance therapy with abacavir + lamivudine + zidovudine in patients with long-term suppression of HIV-1 RNA. 7th Conference on Retro viruses and Opportunistic Infections. San Francisco, USA (2000) (Abstract 457).
   Google Scholar
• ROZENBAUM W, MOLINA JM, DELFRAISSY JF et al.: Improvement of lipodystrophy in HIV- 1-infectedsubjects switching from 2 NRTI/PI to 2NRTI/ abacavir (French substudy, CNA30017). 7th Conference on Retro viruses and Opportunistic Infections. San Francisco, USA (2000) (Abstract 47).
   Google Scholar
• GOEBEL FD, WALLI RK FOR THE CNA30017 STUDY TEAM: A novel use of abacavir to simplify therapy in PI-experienced patients succesfully treated with HAART. 7th Conference on Retro viruses and Opportunistic Infections. San Francisco, USA (2000) (Abstract 51).
   Google Scholar
• VICIANA P, ALARCON D, MARTIN P et al:Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitors to efavirenz. 7th Conference on Retro viruses and Opportunistic Infections. San Francisco, USA (2000) (Abstract 48).
   Google Scholar
• BONNET E, LEPEC R, BLUTEAU R et al.: Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz. 7th Conference on Retro viruses and Opportunistic Infections. San Francisco, USA (2000, (Abstract 49).
   Google Scholar
• MARTINEZ E, GARCIA-VIEJO MA, BLANCO JL et al:Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. an. Infect. Dis. (2000) 31:1266–1273.
   Web of Science ®Google Scholar
• •Effect of switching from protease inhibitors to efavirenz for treating lipodystrophy in HIV-infected patients.
   Google Scholar
• KNOPP RH: Drug treatment of lipid disorders. N Engl. j Med. (1999) 341:498–511.
   PubMed Web of Science ®Google Scholar
• HENRY K, MELROE H, HUEBESCHJ et al.: Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet (1998) 352:1031–1032.
   PubMed Web of Science ®Google Scholar
• •Use of statins and fibrates for treating dyslipidaemia in HIV-infected patients on HAART.
   Google Scholar
• MURILLAS J, MARTIN T, RAMOS A, PORTERO JL: Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS (1999) 13:1424–1425.
   PubMed Web of Science ®Google Scholar
• PISCITELLI SC, GALLICANO KD: Interactions among drugs for HIV and opportunistic infections. N Engl. I Med. (2001)344:984–996.
   Google Scholar
• HERMAN RJ: Drug interactions and the statins. CMAJ(1999) 161:1281–1286.
   PubMed Web of Science ®Google Scholar
• HEWITT RG, SHELTON MJ, ESCH LD: Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS (1999) 13:868–869.
   PubMed Web of Science ®Google Scholar
• MILLER J, CARR A, BROWN D, COOPER DA: A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridemia. 8th Conference on Retro viruses and Opportunistic Infections. Chicago, USA (2001) (Abstract 540).
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet (1998) 352:854–865.
   PubMed Web of Science ®Google Scholar
• SAINT-MARC T, TOURAINE JL: Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS (1999) 13:1000–1002.
   PubMed Web of Science ®Google Scholar
• HADIGAN C, CORCORAN C, BASGOZ N, DAVIS B, SAX P, GRINSPOON S: Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA (2000) 284:472–477.
   PubMed Web of Science ®Google Scholar
• •Randomised, double-blind study on the effect of metformin for treating lipodystrophy in HIV-infected patients.
   Google Scholar
• WALLI R, MICHL GM, MUHLBAYER D et al.: Effects of troglitazone on insulin-sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res. Exp Med. (2000) 199:253–262.
   PubMedGoogle Scholar
• SHEVITZ AH, KNOX TA: Nutrition in the era of highly active antiretroviral therapy. an. Infect. Dis. 2001) 32:1769–1775.
   Web of Science ®Google Scholar
• ROUBENOFF R, WEISS L, MCDERMOTT A et al.:A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS (1999) 13:1373–1375.
   PubMed Web of Science ®Google Scholar
• •Impact of exercise for treating lipodystrophy in HIV-infected patients.
   Google Scholar
• PONCE-DE-LEON S, IGLESIAS M, CEBALLOS J, OSTROSKY-ZEICHNER L: Liposuction for protease-inhibitor-associated lipodystrophy. Lancet (1999) 353-1244.
   Google Scholar
• •First published report on liposuction for treating dorsocervical fat accumulation in HIV-infected patients.
   Google Scholar
• WOLFORT FG, CETRULO CL, NEVARRE DR: Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plast. Reconsm Surg. (1999) 104:1814–1820.
   PubMed Web of Science ®Google Scholar
• LEVAN P, GIRARD PM, ROZEMBAUM W et al:Plastic surgery: facial recontouring in lipodystrophic HIV-infected patients under HAART: our experience. European Symposium 017 Lipodystrophy and HIV Infection. Marrakech, (2000) (Abstract 6).
   Google Scholar
• LEVAN L, GIRARD PM, NGUYEN T et al.: Surgical correction of facial lipoatrophy in patients under HAART. The 1st IAS Conference on HIV pathogenesis and therapy Buenos Aires, (2001) (Abstract 500).
   Google Scholar
• SAINT-MARC T: Effects of polylactic acid (New-Filln on bichat fat pads atrophia in HIV-infected patients under HAART. European Symposium on Lipodystrophy and HIV Infection. Marrakech, (2000) (Abstract 8).
   Google Scholar
• AMARD E SAINT-MARC T, KATZ P: The effects of polylactic acid as therapy for lipoatrophy of the face. 2nd International Workshop on Adverse Dug Reactions and Lipodystrophy in HIV Toronto, Canada (2000) (Abstract P94).
   Google Scholar
• POLO R, VERDEJO J, GONZALEZ-MUNOZ M et al: Lipodystrophy related to reverse transcriptase inhibitors in HAART: effect of switching stavudine therapy. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV San Diego, USA (1999) (Abstract P67).
   Google Scholar
• SAINT-MARC T, TOURAINE JL: The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS (1999) 13:2188–2189.
   PubMed Web of Science ®Google Scholar
• CLARK A: Improvement of facial lipoatrophy after substitution of stavudine. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Toronto, Canada (2000) (Abstract P85).
   Google Scholar
• GARCIA-BENAYAS T, BLANCO F, GOMEZ JM et al: Replacement of stavudine by abacavir does not ameliorate lipoatrophy in HAART recipients. The 1st L45 Conference on HIV pathogenesis and therapy Buenos Aires, Argentina (2001) (Abstract 491).
   Google Scholar
• STROBEL M, MULLER P, CLAUDEL P: Complete reversibility of severe nucleoside-induced lipodystrophy. AIDS (1999) 13:2606–2607.
   PubMed Web of Science ®Google Scholar
• HATANO H, MILLER KD, YODER CP et al.: Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS (2000) 14:1935–1942.
   PubMed Web of Science ®Google Scholar
• DOMINGO P, MATIAS-GUIU X, PUJOL R et al: Switching from protease inhibitors to nevirapine has no effect on HAART-associated subcutaneous adipocyte apoptosis. The 1st L45 Conference on HIV pathogenesis and therapy. Buenos Aires, Argentina (2001) (Abstract 493).
   Google Scholar
• SMITH D, CARR A, LAW M et al: A randomised trial of thymidine analogue withdrawal in lipoatrophic HIV patients, virologically controlled on protease sparing therapy: the PIILR extension study. The 1st IAS Conference on HIV pathogenesis and therapy Buenos Aires, Argentina (2001) (Abstract 96).
   Google Scholar
• ARIOGLU E, DUNCAN-MORIN J, SEBRING N et al: Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann. Intern. Med. (2000) 133:263–274.
   PubMed Web of Science ®Google Scholar
• ••Troglitazone increases subcutaneous fattissue in patients with lipodystrophy not associated with HIV-infection.
   Google Scholar
• MURPHY E, NOLAN JJ: Insulin sensitiser drugs. Exp. Opin. Investig. Drugs (2000) 9:1347–1361.
   PubMed Web of Science ®Google Scholar
• PARULKAR AA, PENDERGRASS ML, GRANDA-AYALA R, LEE TR, FONSECA VA: Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. (2001) 134:61–71.
   PubMed Web of Science ®Google Scholar
• MULLIGAN K, TM VW, SCHAMBELAN M: Use of growth hormone and other anabolic agents in AIDS wasting. JPEN(1999) 23(6 Suppl):5202–209.
   Google Scholar
• RIETSCHEL P, HADIGAN C, CORCORAN C et al:Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. j CM]. Ern/or/Mal. Metab. (2001) 86:504–510.
   PubMed Web of Science ®Google Scholar
• WANKE C, GERRIOR J, KANTAROS J, COAKLEY E, ALBRECHT M: Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS (1999) 13:2099–2103.
   PubMed Web of Science ®Google Scholar
• •Effect of recombinant growth hormone for treating lipodystrophy in HIV-infected patients.
   Google Scholar
• TORRES RA, UNGER KW, CADMAN JA, KASSOUS JY: Recombinant human growth hormone improves truncal adiposity and "buffalo humps" in HIV-positive patients on HAART. AIDS (1999) 13:2479–2481.
   PubMed Web of Science ®Google Scholar
• MAUSS S, WOLF E, JAEGER H: Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone. Ann. Intern. Med. (1999) 131:313–314.
   PubMed Web of Science ®Google Scholar
• SNATOS S: Fat redistribution syndrome and therapy with growth hormone. 3rd International Conference on Nutrition and HIV infection Cannes, France (1999) (Abstract 09).
   Google Scholar
• KNECHTEN H, HOHN C, HOLMGREN-HAAS I, JOPP T, BRAUM I: Effects of low dose recombinant growth hormone on BIA parameters and blood lipids in HIV-infected patients with lipodystrophy. European Symposium 017 Lipodystrophy and HIV _Infection. Marrakech, (2000) (Abstract P01).
   Google Scholar
• SCHAUSTER AC, GELETKO SM, MIKOLICH DJ: Diabetes mellitus associated with recombinant human growth hormone for HIV wasting syndrome. Pharmacotherapy (2000) 20:1129–1134.
   PubMed Web of Science ®Google Scholar
• GOLD J, BATTERHAM M. Nandrolone decanoate: use in HIV-associated lipodystrophy syndrome: a pilot study. Lit. STD. AIDS (1999) 10:558.
   PubMed Web of Science ®Google Scholar
• PADMANABHAN S, ROSENBERG AS: Cushing's syndrome induced by megestrol acetate in a patient with AIDS. Clin Infect. Dis. (1998) 27:217–218.
   PubMed Web of Science ®Google Scholar